BioPharma
AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio
AstraZeneca has gone ahead and committed $100 million to head deeper into the KRAS space by way of securing the right when it comes to a clinical-stage, multitarget asset from Jacobio Pharma of China.
The U.K.-based pharma giant has scored...
BioPharma
Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications
Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.
Business & Industry
Samsung Biologics to Buy US Drug Plant from GSK for $280M
On December 22, 2025, the news has been confirmed of Samsung Biologics to Buy US Drug Plant which is going to be its first US drug production facility from GSK plc for $280 million in order to reduce risks...
Business & Industry
Novartis to Lower Innovative Medicines Price in the US
Novartis, which is a leading global innovative medicines company, went ahead and announced on December 19, 2025, that it has reached an agreement along with the US government that aims to lower innovative medicines price in the US and also...
Business & Industry
New Agreements with Pharmaceuticals Target Lower U.S. Drug Prices
President Donald Trump on December 19, 2025, said that his administration has reached agreements with nine additional pharmaceutical companies, therefore extending a campaign that is aimed at decreasing the prescription drug prices for certain Americans while at the same...
Business & Industry
First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA
The U.S. Food and Drug Administration – FDA on December 22, 2025, gave an approval to the first GLP-1 pill for obesity from Novo Nordisk, the Wegovy maker. This can surely be called a landmark decision, which, as per health...
News
How High-Achievers Stay Future-Ready in Evolving Job Markets
Job markets today are transforming rapidly. In the past few years, we have experienced a paradigmatic shift in the way we work, with the creation of entirely new industries and roles created, along with many jobs being phased out...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















